Medical Therapeutics

DNA Nanobots, LLC

Brief Description

With a portfolio of existing IP, DNA Nanobots develops products for targeted therapeutics and functionalized gene delivery. We have a dual approach, building partnerships to provide development expertise in the functionalization of DNA nanotechnology with experience in Gene Delivery, Vaccine Development, Targeted Drug Delivery, Biosensing, Immunotherapy, and Drug Discovery.

Timeline 2021. Company founded. Inventors

Jennifer Doudna, Enrique Lin Shiao, Rachael Lew

Tessera Therapeutics, Inc.

Brief Description

Developer of gene writing technology designed to permanently make small and large alterations to the human genome. The company's technology helps scientists and clinicians with the ability to write small and large therapeutic messages into the genome to treat diseases at their source, enabling healthcare providers to cure their patients and improve their lives.

Tessera Scientific Advisory Board Member David Schaffer co-invented the company's foundational technology as UC Berkeley Professor of Chemical and Biomolecular Engineering, Bioengineering, Molecular and Cell...

Azalea Therapeutics, Inc.

Brief Description

Azalea Therapeutics is an early-stage biotech startup on a mission to revolutionize genomic medicines. By designing vehicles that enable cell-specific delivery inside the body, the company aims to unlock precision therapeutics for genetic diseases and unleash the promise of cellular-based therapies. The company's co-founders include Jennifer Doudna, a Nobel Laureate in Chemistry and UC Berkeley Professor of Biochemistry, Biophysics and Structural Biology, with Postdocs and a PhD student from her lab: CEO/CSO Jennifer Hamilton (PhD, 2018-2023); Founding Scientist Connor...

Pow.Bio

Brief Description

Pow.Bio provides intelligent fermentation services for industrial and synthetic biology. The company's services combine continuous fermentation with advanced control methodology to quickly optimize the fermentation process and deliver high yields at low cost. The scale runs from 1-100 liter capacity for bacteria, yeast, and filamentous fungi. The first-of-its-kind fermentation technology solves the capacity problem of bioproduction with high-performance continuous fermentation that can run for hundreds of hours. This holy grail of biology offers an order of magnitude step...

Frontier Medicines Corporation

Brief Description

Frontier Medicines was founded to develop medical treatments for currently "undruggable" diseases. The clinical stage precision medicine company pioneers medicines for genetically-defined patient populations in oncology and immunology, and plans to broaden its therapeutic focus over time. The company uses chemoproteomics - an innovative approach to chemically interrogate proteins in living systems – to discover and pharmacologically target new binding pockets (or "hotspots") on proteins, making them accessible to small-molecule drug discovery and development. The...

YourChoice Therapeutics

Brief Description

YourChoice Therapeutics is revolutionizing birth control options for women and men by developing hormone-free contraceptives and bringing them to market. Our technology is the result of a decade of research at the University of California, Berkeley and has been published in numerous high-impact journals.

Timeline 2018. Company founded Inventors

Yuriy Kirichok, Polina Lishko, Nadja Mannowetz, Melissa Miller

Ogma Scientific

Brief Description

Ogma Scientific works with clients in the energy, mining and agriculture sectors and clients in the chemical industry to identify innovative treatment strategies for problems in industrial ecosystems. Our high-throughput screening services are uniquely tailored to identify successful treatments to stop undesirable microbial activity that impacts industrial processes. Examples include biosouring in the oil sector and acid mine drainage in the mining sector. Biosouring alone, caused by the inadvertent stimulation of microbial activity during oil or gas recovery, costs the...

Nurix

Brief Description

Nurix is pioneering rational drug design in the emerging field of protein regulation by targeting E2 conjugating enzymes and E3 ligases that control the Ubiquitin Proteasome System (UPS).

Regulation of protein stability by the UPS is modulated by the activity of these E2 and E3 enzymes, which control the tagging of proteins with ubiquitin for degradation by the proteasome. The human genome encodes approximately 1,000 different E3 ligases and 60 E2 enzymes. A number of these ligases recently have been shown to play key roles in human diseases, particularly in cancer...

suitX

Brief Description

suitX brought advanced accessible exoskeletons to industrial and medical markets with funding from venture capital, industry, and government.

Formerly known as U.S. Bionics.

Acquired by Ottobock in 2021.

Timeline 2011. Company founded. 2021. Acquired by Ottobock. Inventors

Homayoon Kazerooni, Adam Zoss, Andre Nguyen Van Qui, Bradley Perry, Christina Yee, Daniel Merala, David Cuban, Dong-Jin Hyun, Dylan Fairbanks, Erich Hacker, Han Woong Bae, James Alden Hatch, Jason Reid, JiaLong James Ren, Jing Song Huang, JJ Kuwata...

Stylus Medicine

Brief Description

Stylus Medicine is on a mission to develop next-generation therapies for disease, based on the pioneering work of leaders in the fields of genome engineering and chromatin regulation.

Timeline 2022. Company founded. Inventor

Patrick David Hsu